In any case, the combined blockade of CTLA-4 and GITR with mAb was recently shown to synergistically reduce tumor formulation in two different murine tumor models, demonstrating that their respective effects on Tregs and effector T cells, in the end, work together [144]. The gene discussed is TNFRSF18; the disease is neoplasm.